Ovarian reserve in Fragile X premutation carriers
Part of Genetic & congenital, Women’s health & pregnancy clinical trials.
This study looks at egg supply (ovarian reserve) in women who carry the Fragile X premutation. It aims to understand fertility potential better and help guide future family planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between the ages of 18 and 40.
- You carry the Fragile X premutation (any number of CGG repeats is okay).
- You have not had any ovarian surgery, radiotherapy, chemotherapy, or endometriosis that could affect your ovaries.
- You are enrolled in a social security plan (or equivalent) and are not under legal guardianship or protection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how common endometriosis and adenomyosis are in women who preserve their fertility for non-medical reasons. It may help understand these conditions better.
This study compares egg supply (“ovarian reserve”) in women with multiple sclerosis to women without MS. It may help doctors understand how MS affects reproductive health and egg supply.
This study looks at DNA changes to understand the cause of premature ovarian insufficiency (early menopause). It may help clarify what’s happening in your body and guide future care.
This study measures blood biomarkers to understand how breast cancer treatment affects a person’s future fertility (ovarian reserve). It may help patients learn more about egg supply changes after chemotherapy and hormone-related treatments.
This study looks at how BRCA gene changes (mutations) may affect fertility in women. By comparing women with BRCA mutations to their relatives without the mutation, researchers hope to learn more about fertility and family planning for those affected.
This study looks at the genes that may cause premature ovarian insufficiency (POI), a condition where the ovaries stop working before age 40. The researchers will compare the genes of women with POI to those with normal ovarian function, which may lead to better understanding and future treatments.
Hear when a new FMR1 Gene Premutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.